http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
한국인 정신분열병 환자의 지연성 운동장애와 $CYP2D6^*4$ 및 $CYP2D6^*10$ 다형성들의 연합에 대한 고찰
우성일,강동우,서한길,김봉조,이인상,정근화,박소영,정치영,이환철,정경천,손진욱,Woo, Sung-Il,Kang, Dong-Woo,Seo, Han-Gil,Kim, Bong-Jo,Lee, In-Sang,Jeong, Geun-Hoa,Park, So-Young,Jung, Chi-Yeong,Lee, Hwan-Cheol,Jeong, Kyeong-Cheon,Sohn, 대한생물정신의학회 2000 생물정신의학 Vol.7 No.2
P450 CYP2D6 enzyme(=debrisoquine hydroxylase) is known to metabolize many neuroleptics and some genetic polymorphisms in the CYP2D6 gene were reported to be associated with tardive dyskinesia(TD). We investigeted the association of two genetic polymorphisms in the CYP2D6 gene, $CYP2D6^*4$ and $CYP2D6^*10$, with TD in Korean schizophrenic subjects. Subjects consisted of 71 Korean schizophrenics and TD was evaluated using the Abnormal Involuntary Movement Scale (AIMS). There were no statistically significant differences in the demographic variables of age, male to female percentage and the current antipsychotic(CPZ equivalent) dose between the group with TD and the group without TD. But the duration of antipsychotic drug exposure was significantly higher in the group without TD(p=0.000, by independent t-test). The mean AIMS score in the group with TD was $11.2{\pm}6.6$(S.D.). Genotypings for the presence of $CYP2D6^*4$ and $CYP2D6^*10$ were done using PCR amplifications and endonuclease digestions. There were no statistically significant genotypic and alleleic associations between TD and $CYP2D6^*4$(by chisquare tests), and between TD and $CYP2D6^*10$(by chi-square tests). These results indicate that the $CYP2D6^*4$ and $CYP2D6^*10$ polymorphisms have no significant roles in the causation of TD.
Expression Pattern of the PML/RARαFusion Gene in Acute Promyelocytic Leukemia
Han, Chi Hwa,Lee, Jong Wook,Jin, Jong Youl,Kim, Dong Wook,Kim, Dong Jip,Kim, Chun Choo,Yang, Il Ho,Park, Chong Won,Kim, Hack Ki,Min, Woo Sung,Kim, Won Il CATHOLIC MEDICAL CENTER 1994 Bulletin of the Clinical Research Institute Vol.22 No.2
The molecular characterization of the translocations involved in hematopoietic tumors has advanced our understanding of neoplastic transformation. Acute promyelocytic leukemia (APL; AML M3) is identified by a unique t (15; 17) translocation which fuses the PML gene to the retinoic acid receptor alpha gene (RARα) and a consistent translocation is present in the blasts of the majority of APL patients. The t (15; 17) translocation generates a PML/RARα chimeric gene that is transcribed as a fusion PML/RARα messenger. RNA. The detection of the PML/RARα rearrangements involved in APL has not only provided pathogenetic marker but also permitted more accurate diagnosis and monitoring of the patient's response to therapy. Reverse transcription coupled with the polymerase chain reaction (RT/PCR) has been used to develop a diagnostic test for APt based on the PML/RARα fusion message. Using primer sets derived from RARα and PML cDNAS, we were able to amplify the breakpoint sites of the fusion transcripts of all 20 APL RNA samples by RT/PCR and multiple nested primer sets approach of two rounds of amplification. DNA fragments of different size were obtained according to the chromosome 15 breakpoints. The results are as follows: 1. The present investigation shows that multiple chromosome 15 (PML) and 17 (RARα) derived nested primer sets allow the translocation breakpoints to be identified in all APL patients. 2. Breakpoint cluster regions are more than 3 sites. The incidence of bcr 1, bcr 2, bcr 3, and bcr 4 was 25%, 15%, 30%, and 30% respectively, which is different from the other reports. 3. New breakpoint cluster region is identified as bcr 4. bcr 4 breakpoint occured in PML gene intron 4 which was not reported in other papers. The incidence of bcr 4 is relatively higher than other breakpoints in our study, and furthur studies including nucleotide sequencing ananlysis should be followed. 4. The feasibility of monitoring of the response to therapy by PCR analysis in three APL patients, one of them had allogeneic bone marrow transplantation and two received chemotherapy, was evaluated in complete remission state. PML/RARα positive cells could be detected by RT/PCR analysis in post chemotherapy remission state, but there are no PML/RARα positive cells in bone marrow transplantation case. We conclude that the PML/RARα express at least three types of PML/RARα messenger RNA, and more studies are needed about the newly observed bcr 4 breakpoint found in PML intron 4. The amplification of the PML/RARα junctions can be used for the easiest and rapid method for the diagnosis and monitoring the therapeutic effectiveness of the APL.
FT-IR and XRD Analyses of Commercial Methionine-Mineral Chelates
Han, Jae-Hong,Chi, Yong-Seok,Shin, Bok-Kyu,Kim, Sang-Kyu,Paik, In-Kee The Korean Society for Applied Biological Chemistr 2006 Journal of Applied Biological Chemistry (J. Appl. Vol.49 No.1
Compositions of methionine-metal chelates have been investigated by FT-IR and XRD studies to elucidate their molecular structures. It was concluded that Copamin and Zincamin contain a high percentage of crystalline products, presumably 2:1 Methionine-Cu or Zn complexes. On the contrary, FT-IR and XRD spectra of Ferramin didn't show any characteristics of the chelate and it was concluded to contain major components of starting $FeSO_4$ and methionine without chelation.